List view / Grid view
Novartis announced that the European Commission approved ribociclib in combination…
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with…
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
Novartis announced the appointment of Bruno Strigini, as President of…
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
The European Commission approved VICTRELIS™ (boceprevir)...
18 July 2011 | By Merck
The European Commission approved VICTRELIS™ (boceprevir)...
